Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

Will Resubmit With New Data from Ongoing Studies

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced the withdrawal of the European application to extend the Evoltra(R) (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.

In a letter to the European Medicines Agency (EMEA) on behalf of Bioenvision, Genzyme states that the withdrawal is based on the EMEA's Committee for Medicinal Products for Human Use (CHMP) assessment that the data from the BIOV121 study are not sufficient to support a recommendation for market approval at this time. Bioenvision is now a wholly-owned subsidiary of Genzyme.

"As we expected, the filing that Bioenvision submitted to the EMEA was not sufficient to support approval in adult AML and our subsequent conversations with the CHMP have confirmed this assessment," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corp. "We have engaged in a positive dialogue with the Rapporteurs regarding the requirements for approval and will develop a new submission to include data from one or more ongoing clinical studies of clofarabine in this patient population for submission possibly as early as the fourth quarter of this year."

In the United States, Genzyme has completed enrollment for a pivotal study in previously untreated, older adult patients with AML who are unlikely to benefit from standard intensive induction chemotherapy. Data from this study, known as CLASSIC II, are expected to provide substantial evidence for expa
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Steep Hill, ... the US and internationally, intends to open a full ... Albuquerque, New Mexico , bringing advanced scientific tools ... cannabis. Steep Hill is currently the only ... to conduct potency and contaminant testing in order to ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today reported 2014 full ... key objectives, and financial guidance.  Synageva,s management team ... p.m. EST to review the financial results and ... today,s call by telephone, please dial (877) 445-4603 ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Md., Dec. 19 Dr. Joseph,Corriveau was recently ... Chemical Biological Center (ECBC). With this appointment, Dr.,Corriveau ... of the SES,serve in key positions just below ... the appointees and the federal work force., ...
... LifeCell,Corporation (Nasdaq: LIFC ), today announced ... 2008 financial guidance on Monday, January,7, 2008 at ... Executive,Officer, will host a conference call at 10:00 ... revenues and expected financial performance,for 2008., The ...
... Have Been Resolved; Remaining Issues Pertain to ... Third-party Manufacturing Facility Company Expects to Resolve ... Mass., Dec. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... from the U.S. Food and Drug Administration (FDA) for,VALSTAR(TM) ...
Cached Biology Technology:Dr. Joseph L. Corriveau Appointed Director of Research and Technology 2LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... For hundreds of years, naturalists and scientists ... visible differences. But now, new genetic techniques are ... no visible differences. In a just-published study, ... and the American Museum of Natural History (AMNH) ...
... N.C. , March 11, 2013  Wake Forest ... related to its commercialization enterprise, Wake Forest Innovations, ... Triad Research Park.   Wake Forest Innovation ... beyond the community and an analysis of park ...
... 2013- BGI Tech Solutions Co., Ltd., also referred ... assembly solution for facilitating heterozygous genomes research. This ... genome assembly after the completed genome sequencing of ... a reference genome for a species is the ...
Cached Biology News:Researchers develop tools for discovering new species 2Researchers develop tools for discovering new species 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... rat adult and fetal tissue, ... * T75 plated cells $750.00, ... This product requires Celprogen Stem ... and extracellular matrix, * E55007-08-T25 ...
... Bacterial DNA Isolation Kit provides a rapid ... genomic DNA from the various bacterial species ... the isolation of genomic DNA from both ... milk samples. ,Purification is based on ...
Biology Products: